Wilsey Asset Management Inc. Boosts Holdings in Pfizer Inc. $PFE

Wilsey Asset Management Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 1,390,058 shares of the biopharmaceutical company’s stock after purchasing an additional 202,641 shares during the quarter. Pfizer comprises about 4.9% of Wilsey Asset Management Inc.’s holdings, making the stock its 13th largest position. Wilsey Asset Management Inc.’s holdings in Pfizer were worth $33,473,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. raised its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the 4th quarter worth $26,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Global Trust Asset Management LLC increased its position in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares during the last quarter. Finally, Abound Financial LLC purchased a new stake in Pfizer in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat and guidance increase: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Management raised the low end of its 2026 revenue outlook, supported by Eliquis and other non-COVID products. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Cost savings and pipeline support: Pfizer expanded its cost-reduction target, providing a potential lift to future margins and cash flow. Analysts also highlighted continued growth in newer products and a broader R&D pipeline as offsets to declining COVID revenue. PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
• Positive Sentiment: Clinical catalysts: Pfizer reported positive Phase 3 data for LITFULO in vitiligo and announced progress in a pediatric COVID booster study. It also completed a Phase 1 study of PF-07328948, adding incremental support to its longer-term pipeline narrative. Pfizer Reports Positive Phase 3 LITFULO Data in Vitiligo
• Neutral Sentiment: Analyst view remains mixed: Some coverage describes Pfizer as attractive for income investors because of its high dividend yield and potential undervaluation, while RBC Capital maintained a Hold rating. Investors remain focused on execution and the sustainability of the recovery. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and pipeline risks persist: COVID pill revenue reportedly fell 95%, and setbacks surrounding Pfizer’s obesity program, along with upcoming patent expirations, continue to raise concerns about long-term growth. These risks explain why the market’s response remains measured despite the earnings beat. Pfizer Covid Pill Revenue Plunges 95%

Analysts Set New Price Targets

Several brokerages have weighed in on PFE. Guggenheim lowered their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. UBS Group restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Finally, Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.50.

Pfizer Stock Up 1.4%

Pfizer stock opened at $26.18 on Friday. The firm has a market capitalization of $149.24 billion, a P/E ratio of 34.45 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The stock’s fifty day simple moving average is $25.01 and its 200-day simple moving average is $26.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business posted $0.78 earnings per share. Pfizer’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s payout ratio is currently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.